Amcad Biomed's revenue for the
three
months ended in Jun. 2024 was NT$16.37 Mil.
Its revenue for the trailing twelve months (TTM) ended in Jun. 2024 was NT$63.57 Mil.
Amcad Biomed's Revenue per Share for the
three
months ended in Jun. 2024 was NT$0.30.
Its Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2024 was NT$1.16.
Warning Sign:
Amcad Biomed Corp revenue per share has been in decline for the last 5 years.
During the past 12 months, the average Revenue per Share Growth Rate of Amcad Biomed was 18.60% per year.
During the past 3 years, the average Revenue per Share Growth Rate was 0.60% per year.
During the past 5 years, the average Revenue per Share Growth Rate was -3.40% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate using Revenue per Share data.
During the past 13 years, Amcad Biomed's highest 3-Year average Revenue per Share Growth Rate was 664.00% per year. The lowest was -54.60% per year. And the median was 5.60% per year.
Amcad Biomed Revenue Historical Data
The historical data trend for Amcad Biomed's Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Amcad Biomed's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Amcad Biomed's Revenue Distribution in the Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Amcad Biomed's Revenue distribution charts can be found below:
* The bar in red indicates where Amcad Biomed's Revenue falls into.
Amcad Biomed Revenue Calculation
Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.
Revenue for the trailing twelve months (TTM) ended in Jun. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$63.57 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Amcad Biomed (ROCO:4188) Revenue Explanation
In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.
Peter Lynch categorized companies according to their revenue growth:
His favorite companies are stalwart, those growing between 10-20% a year.
Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.
Be Aware
Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.
Amcad Biomed Revenue Related Terms
Thank you for viewing the detailed overview of Amcad Biomed's Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
Amcad Biomed Corp develops computer-aided detection and diagnosis(CADe/CADx) software devices. Its product pipeline includes AmCAD-UT Detection, a software solution for thyroid nodules analysis; AmCAD-UV, a software device that is used for quantifying and classifying the ultrasonic color intensity data acquired from FDA-cleared ultrasound systems and displaying the noise-reduced color-coded pulsatile signals; AmCAD- U.S, a software device for viewing and quantifying ultrasound image data of backscattered signals; and AmCAD-UO offers detection for obstructive sleep apnea on awake patients to identify the root cause of sleep apnea. The company's geographical segments include Taiwan, China, and other countries, out of which the majority of the revenue is generated from China.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
ROCO:4188 has been successfully added to your 